Crossject is revolutionizing the administration of well-established, clinically-proven treatments and bringing unprecedented advantages to patients with its innovative, needle-free auto-injector ZENEO®.
ZENEO® is no less than 12 years of R&D and more than 400 obtained patents.
Currently, 8 treatments are in advanced stages of development, which 7 for emergency situations.
With its unique know-how, Crossject aims to become a world leader in the self-administration of emergency needle free injectables.
Parc Mazen-Sully 6 Rue Pauline Kergomard, 21000 Dijon – France
|Trading entity / Person
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.